Lopinavir

Breastfeeding

See adverse reactions attributed to class:

Antiretroviral

COVID-19 putative drug

HIV-1 protease inhibitor

Kaletra is lopinavir and ritonavir.

Dermatitis 

(2005): Calista D, Eur J Dermatol 15(2), 97 (with ritonavir)

Jaundice 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Lipodystrophy <10%

(package insert)

Rash <10%

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

(2014): Cai J+, Chin Med J (Engl) 127(14), 263269% (with lamivudine, ritonavir and zidovudine)

(2014): Santini-Oliveira M+, Expert Opin Drug Saf 13(12), 1623 [REVIEW] (with ritonavir)

(2008): Borras-Blasco J+, J Antimicrob Chemother 62(5), 879 (with ritonavir)

(2005): Calista D, Eur J Dermatol 15(2), 97 (with ritonavir)

Toxicity 

(2014): Martin-Carbonero L+, HIV Clin Trials 15(2), 576%

Alopecia 

(2007): Borras-Blasco+, Pharmacotherapy 27(8), 1215

(2007): Chrysos G+, J Drugs Dermatol 6(7), 742

(2003): Bongiovanni M+, Dermatol Online J 9(5), 28 (with ritonavir)

Alopecia areata 

(2014): Kim HS+, Infect Chemother 46(2), 103 (with ritonavir)

Nail pigmentation 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Oropharyngeal pain 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Sialorrhea (ptyalism; hypersalivation) 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Arrhythmias 

(2009): Chaubey SK+, Sex Health 6(3), 254

Cardiotoxicity 

(2009): McArthur MA+, Pediatr Infect Dis J 28(12), 1127 (in neonatal twins / with ritonavir)

Sick sinus syndrome 

(2013): Sasaki S+, Kansenshogaku Zasshi (Japanese) 87(5), 613 (2 cases) (with ritonavir)

Vasoconstriction 

(2014): Ferry FR+, Rev Inst Med Trop Sao Paulo 56(3), 265 (with ergotamine and ritonavir)

Anorexia 

(2015): Tetteh RA+, BMC Public Health 15(1), 5736% (with lamivudine, ritonavir and zidovudine)

Fever (pyrexia) 

(2015): Tetteh RA+, BMC Public Health 15(1), 5736% (with lamivudine, ritonavir and zidovudine)

Headache 

(2015): Tetteh RA+, BMC Public Health 15(1), 57310% (with lamivudine, ritonavir and zidovudine)

Insomnia 

(2015): Tetteh RA+, BMC Public Health 15(1), 5734% (with lamivudine, ritonavir and zidovudine)

Restlessness 

(2015): Tetteh RA+, BMC Public Health 15(1), 5734% (with lamivudine, ritonavir and zidovudine)

Somnolence (drowsiness) 

(2015): Tetteh RA+, BMC Public Health 15(1), 5736% (with lamivudine, ritonavir and zidovudine)

Vertigo / dizziness 

(2015): Rattanapunya S+, Malar J 14(1), 400 (with artesunate, mefloquine and ritonavir)

(2015): Tetteh RA+, BMC Public Health 15(1), 5738% (with lamivudine, ritonavir and zidovudine)

Appetite decreased 

(2015): Tetteh RA+, BMC Public Health 15(1), 57310% (with lamivudine, ritonavir and zidovudine)

Cushing's syndrome 

(2007): Bhumbra NA+, Ann Pharmacother 41(7), 1306Pediatric (with fluticasone and ritonavir)

Diabetes mellitus 

(2014): Santini-Oliveira M+, Expert Opin Drug Saf 13(12), 1623 [REVIEW] (with ritonavir)

Hyponatremia 

(2007): Roberts MT+, Int J Infect Dis 11(1), 83-4

Miscarriage 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Abdominal pain 

(2015): Tetteh RA+, BMC Public Health 15(1), 57314% (with lamivudine, ritonavir and zidovudine)

Diarrhea >10%

(2015): Tetteh RA+, BMC Public Health 15(1), 57365% (with lamivudine, ritonavir and zidovudine)

(2014): Clumeck N+, AIDS 28(8), 114315% (with ritonavir)

(2013): Orkin C+, HIV Med 14(1), 4911% (with ritonavir)

(2012): Wegzyn CM+, J Int Assoc Physicians AIDS Care (Chic) 11(4), 25216% (with ritonavir)

(2009): Nunes EP+, HIV Clin Trials 10 (6), 368

Flatulence <10%

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Gastritis 

(2014): Cahn P+, Lancet Infect Dis 14(7), 572 (serious / 1 case) (with lamivudine and ritonavir)

Gastrointestinal disorder 

(2020): Chouchana L+, Ther Drug Monit Nov, Online ahead of print (with ritonavir)

Hepatic disorder 

(2020): Chouchana L+, Ther Drug Monit Nov, Online ahead of print (with ritonavir)

Hepatotoxicity 

(2014): Cai J+, Chin Med J (Engl) 127(14), 263239% (with lamivudine, ritonavir and zidovudine)

Nausea <10%

(2015): Rattanapunya S+, Malar J 14(1), 400 (with artesunate, mefloquine and ritonavir)

(2015): Tetteh RA+, BMC Public Health 15(1), 57371% (with lamivudine, ritonavir and zidovudine)

(2014): Clumeck N+, AIDS 28(8), 114319% (with ritonavir)

(2010): Zajdenverg R+, J Acquir Immune Defic Syndr 54 (2), 143

Pancreatitis 

(2008): Anand H+, J Postgrad Med 54(2), 153

(2008): Bhargava P, J Postgrad Med 54(3), 241

Vomiting  <10%

(2015): Rattanapunya S+, Malar J 14(1), 400 (with artesunate, mefloquine and ritonavir)

(2015): Tetteh RA+, BMC Public Health 15(1), 57335% (with lamivudine, ritonavir and zidovudine)

(2014): Clumeck N+, AIDS 28(8), 114313% (with ritonavir)

Bleeding 

(2015): Tetteh RA+, BMC Public Health 15(1), 573 (with lamivudine, ritonavir and zidovudine)

Asthenia / fatigue <10%

(2015): Tetteh RA+, BMC Public Health 15(1), 57310–27% (with lamivudine, ritonavir and zidovudine)

(2014): Cai J+, Chin Med J (Engl) 127(14), 263289% (with lamivudine, ritonavir and zidovudine)

Neck pain 

(2015): Tetteh RA+, BMC Public Health 15(1), 5732% (with lamivudine, ritonavir and zidovudine)

Osteomalacia 

(2013): Lucey JM+, BMJ Case Rep Jul, Epub (with emtricitabine, ritonavir and tenofovir)

Tendinopathy/Tendon rupture 

(2014): Cresswell FV+, Int J STD AIDS 25(11), 833 (with ritonavir)

Fanconi syndrome 

(2013): Lucey JM+, BMJ Case Rep Jul, Epub (with emtricitabine, ritonavir and tenofovir)

Nephrolithiasis 

(2014): Izzedine H+, Clin Kidney J 7(2), 121 [REVIEW]

(2004): Doco-Lecompte T+, AIDS 18(4), 705 (with ritonavir)

Nephrotoxicity 

(2015): Chughlay MF+, AIDS 29(4), 503 (with ritonavir)

(2014): Santini-Oliveira M+, Expert Opin Drug Saf 13(12), 1623 [REVIEW] (with ritonavir)

Renal failure 

(2014): Krishna MM+, Indian J Pharmacol 46(2), 230 (delayed / with emtricitabine, ritonavir and tenofovir)

Adverse effects 

(2014): Cai J+, Chin Med J (Engl) 127(14), 2632 (gastrointestinal / with lamivudine, ritonavir and zidovudine)



Adverse reactions attributed to entire drug class Antiretroviral

Hematological adverse effect 

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83115%

Optic neuropathy 

(2013): Wang MY+, J Neuroophthalmol 33(2), 172 [REVIEW]

Adverse effects 

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83142%

(2014): Lorio M+, J Int Assoc Provid AIDS Care 13(5), 4666%

Adverse reactions attributed to entire drug class COVID-19 putative drug

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Neuropsychiatric disturbances 

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Adverse effects 

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zekarias A+, Drug Saf Sep, Online ahead of print [REVIEW]

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Adverse reactions attributed to entire drug class HIV-1 protease inhibitor

Eczema 

(2015): Descamps V+, Br J Dermatol 173(1), 311

Xerosis 

(2015): Descamps V+, Br J Dermatol 173(1), 311

Page last updated 11/26/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top